Parabolic gets certificate of suitability for Cefixime

Parabolic Drugs said on Monday it has received a certificate of suitability (COS) for its key molecule Cefixime in the European Union.

April 18, 2011 / 16:32 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Parabolic Drugs said on Monday it has received a certificate of suitability (COS) for its key molecule Cefixime in the European Union.

The COS would enable the company to expand its presence in regulated markets, it said in a statement to the National Stock Exchange.

Cefixime, an oral third generation cephalosporin antibiotic, has a global market size of USD 839 million, growing at 20.9% annually and is used in the treatment of gonorrhea, tonsilitis and pharyngitis, it added.

The European market contributes to over 18% in total sales for this molecule, it said.

At 10.47 am, shares in the firm were up 3.6% at Rs 48.5 in a firm Mumbai market.

first published: Apr 18, 2011 03:29 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347